Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
Annals of Neurology|January 31, 2007
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosisFlavia Nelson, Mohammad A Akhtar, Edward Zúñiga, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 yearsFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Annals of Neurology|February 21, 2013
Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 26, 2013
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous systemLarry A Kramer, Alan M Cohen, Khader M Hasan, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Annals of Clinical and Translational Neurology|February 17, 2025
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosisAhmed Bayoumi, Joseph A Thomas, Breanna R Alonzo, et al.
Pageof 14